Identification of the Novel Variants in Patients With Chronic Thromboembolic Pulmonary Hypertension

Background Although chronic thromboembolic pulmonary hypertension (CTEPH) and acute pulmonary embolism (APE) share some clinical manifestations, a limited proportion of patients with CTEPH have a history of APE. Moreover, in histopathologic studies, it has been revealed that pulmonary vasculature lesions similar to pulmonary arterial hypertension existed in patients with CTEPH. Thus, it remains unknown whether these 3 disorders also share genetic backgrounds. Methods and Results Whole exome screening was performed with DNA isolated from 51 unrelated patients with CTEPH of Japanese ancestry. The frequency of genetic variants associated with pulmonary arterial hypertension or APE in patients with CTEPH was compared with those in the integrative Japanese Genome Variation Database 3.5KJPN. Whole exome screening analysis showed 17 049 nonsynonymous variants in patients with CTEPH. Although we found 6 nonsynonymous variants that are associated with APE in patients with CTEPH, there was no nonsynonymous variant associated with pulmonary arterial hypertension. Patients with CTEPH with a history of APE had nonsynonymous variants of F5, which encodes factor V. In contrast, patients with CTEPH without a history of APE had a nonsynonymous variant of THBD, which encodes thrombomodulin. Moreover, thrombin‐activatable fibrinolysis inhibitor, which is one of the pathogenic proteins in CTEPH, was significantly more activated in those who had the variants of THBD compared with those without it. Conclusions These results provide the first evidence that patients with CTEPH have some variants associated with APE, regardless of the presence or absence of a history of APE. Furthermore, the variants might be different between patients with CTEPH with and without a history of APE.

[1]  W. Chung,et al.  Genetics and other omics in pediatric pulmonary arterial hypertension. , 2020, Chest.

[2]  J. Barberà,et al.  The ADAMTS13–VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension , 2019, European Respiratory Journal.

[3]  S. Miyata,et al.  Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term effects and procedure-related complications , 2017, European heart journal.

[4]  R. Kurosawa,et al.  Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target , 2017, Circulation research.

[5]  K. Fukuda,et al.  Familial Chronic Thromboembolic Pulmonary Hypertension in a Pair of Japanese Brothers. , 2016, Chest.

[6]  Zhongming Zhao,et al.  Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension. , 2016, American journal of respiratory and critical care medicine.

[7]  K. Kerr,et al.  Chronic Thromboembolic Pulmonary Hypertension. Epidemiology and Risk Factors. , 2016, Annals of the American Thoracic Society.

[8]  S. Miyata,et al.  Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[9]  A. Hemnes,et al.  Current Concepts in the Pathogenesis of Chronic Thromboembolic Pulmonary Hypertension , 2016, Pulmonary circulation.

[10]  C. Elliott,et al.  Familial Chronic Thromboembolic Pulmonary Hypertension. , 2016, Chest.

[11]  Zhihong Liu,et al.  High Frequency of Pulmonary Hypertension-Causing Gene Mutation in Chinese Patients with Chronic Thromboembolic Pulmonary Hypertension , 2016, PloS one.

[12]  Kengo Kinoshita,et al.  Rare variant discovery by deep whole-genome sequencing of 1,070 Japanese individuals , 2015, Nature Communications.

[13]  Fumiki Katsuoka,et al.  An efficient quantitation method of next-generation sequencing libraries by using MiSeq sequencer. , 2014, Analytical biochemistry.

[14]  S. Miyata,et al.  Platelets Are Highly Activated in Patients of Chronic Thromboembolic Pulmonary Hypertension , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[15]  M. Madani,et al.  Update on chronic thromboembolic pulmonary hypertension. , 2014, Circulation.

[16]  J. Loyd,et al.  The Genetics of Pulmonary Arterial Hypertension , 2014, Circulation research.

[17]  Maya B. Mathur,et al.  Whole-exome sequencing reveals TopBP1 as a novel gene in idiopathic pulmonary arterial hypertension. , 2014, American journal of respiratory and critical care medicine.

[18]  R. Bertina,et al.  Functional Analysis of Two Haplotypes of the Human Endothelial Protein C Receptor Gene , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[19]  W. Chung,et al.  The genetic basis of pulmonary arterial hypertension , 2014, Human Genetics.

[20]  Toru Satoh,et al.  Definitions and diagnosis of pulmonary hypertension. , 2013, Journal of the American College of Cardiology.

[21]  N. Tanabe,et al.  Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension. , 2013, Respiratory investigation.

[22]  N. Morrell,et al.  Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension. , 2013, American journal of respiratory cell and molecular biology.

[23]  R. Bertina,et al.  Association of the Thrombomodulin Gene c.1418C>T Polymorphism With Thrombomodulin Levels and With Venous Thrombosis Risk , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[24]  W. Chung,et al.  Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension , 2013, Nature Genetics.

[25]  S. Sakao,et al.  Crosstalk between endothelial cell and thrombus in chronic thromboembolic pulmonary hypertension: perspective. , 2013, Histology and histopathology.

[26]  W. Chung,et al.  Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated With Human Pulmonary Arterial Hypertension , 2012, Circulation. Cardiovascular genetics.

[27]  J. Yuan,et al.  New mechanisms of pulmonary arterial hypertension: role of Ca²⁺ signaling. , 2012, American journal of physiology. Heart and circulatory physiology.

[28]  J. Barberà,et al.  Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Results From an International Prospective Registry , 2011, Circulation.

[29]  William W. Cohen,et al.  KNG1 Ile581Thr and susceptibility to venous thrombosis. , 2011, Blood.

[30]  F. Rosendaal,et al.  New gene variants associated with venous thrombosis: a replication study in White and Black Americans , 2011, Journal of thrombosis and haemostasis : JTH.

[31]  W. Klepetko,et al.  Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. , 2011, The Journal of thoracic and cardiovascular surgery.

[32]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[33]  Georg Heinze,et al.  Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism: The Vienna Prediction Model , 2010, Circulation.

[34]  M. Laffan,et al.  Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension , 2010, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[35]  M. Hersberger,et al.  Sequence Variants in BMPR2 and Genes Involved in the Serotonin and Nitric Oxide Pathways in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Relation to Clinical Parameters and Comparison with Left Heart Disease , 2009, Respiration.

[36]  T. Kuriyama,et al.  HLA-DPB1 and NFKBIL1 may confer the susceptibility to chronic thromboembolic pulmonary hypertension in the absence of deep vein thrombosis , 2009, Journal of Human Genetics.

[37]  J. González-Porras,et al.  Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. , 2007, Blood.

[38]  H. Vos Inherited defects of coagulation Factor V: the thrombotic side , 2006, Journal of thrombosis and haemostasis : JTH.

[39]  N. Rudarakanchana,et al.  Dysfunctional Smad Signaling Contributes to Abnormal Smooth Muscle Cell Proliferation in Familial Pulmonary Arterial Hypertension , 2005, Circulation research.

[40]  T. Kuriyama,et al.  Association of clinical features with HLA in chronic pulmonary thromboembolism , 2005, European Respiratory Journal.

[41]  Paolo Prandoni,et al.  Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. , 2004, The New England journal of medicine.

[42]  Seong-Jin Kim,et al.  Isolation of a regulatory region of activin receptor-like kinase 1 gene sufficient for arterial endothelium-specific expression. , 2004, Circulation research.

[43]  M. Humbert,et al.  Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension , 2004, Thorax.

[44]  J. Meijers,et al.  Thrombin‐activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U) , 2003, Journal of thrombosis and haemostasis : JTH.

[45]  R. Bertina,et al.  The R2-haplotype associated Asp2194Gly mutation in the light chain of human factor V results in lower expression levels of FV, but has no influence on the glycosylation of Asn2181 , 2003, Thrombosis and Haemostasis.

[46]  E. Nizankowska-Mogilnicka,et al.  Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis , 2003, European Respiratory Journal.

[47]  M. Myśliwiec,et al.  Renal function, proteinuria and ACE-inhibitor therapy as determinants of plasma levels of endothelial markers. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[48]  R. Trembath,et al.  Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.

[49]  G. Simonneau,et al.  Thrombotic risk factors in pulmonary hypertension. , 2000, The European respiratory journal.

[50]  L. Jorfeldt,et al.  Pulmonary embolism: one-year follow-up with echocardiography doppler and five-year survival analysis. , 1999, Circulation.

[51]  V. Nicaud,et al.  The Factor V Gene A4070G Mutation and the Risk of Venous Thrombosis , 1999, Thrombosis and Haemostasis.

[52]  K. Moser,et al.  Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. , 1993, Chest.

[53]  C. Esmon,et al.  Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Yongzhe Li,et al.  Relationship of HLA-B*51 and HLA-B*52 alleles and TNF-α-308A/G polymorphism with susceptibility to Takayasu arteritis: a meta-analysis , 2016, Clinical Rheumatology.

[55]  Y. Kokubo,et al.  Haplotype of thrombomodulin gene associated with plasma thrombomodulin level and deep vein thrombosis in the Japanese population. , 2007, Thrombosis research.

[56]  S. Ohdama,et al.  Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases. , 1994, American journal of clinical pathology.